Randomized prospective matched pair study comparing peritoneovenous shunt and conventional therapy in massive...

Area of Science:

• Gastroenterology and Hepatology
• Surgical Innovation
• Clinical Efficacy Studies

Background:

• Massive cirrhotic ascites poses significant challenges in patient management.
• Traditional medical therapy often proves insufficient for refractory ascites.
• The peritoneovenous (LeVeen) shunt offers a surgical alternative for managing ascites.

Purpose of the Study:

• To evaluate the efficacy of the peritoneovenous (LeVeen) shunt versus traditional medical therapy for massive cirrhotic ascites.
• To compare key clinical outcomes including fluid management, survival, and hospitalization.
• To identify patient subgroups who may not be suitable candidates for the surgical procedure.

Main Methods:

• Prospective randomized matched pair study design.
• Inclusion criteria: patients with massive cirrhotic ascites refractory to medical management (low salt diet, 1000 ml fluid restriction).
• Comparison between LeVeen shunt surgery and continued medical therapy.

Main Results:

• Surgical intervention demonstrated significantly greater weight loss, abdominal girth reduction, and diuresis (P < 0.01).
• LeVeen shunt patients exhibited improved survival rates (12/14 pairs, P < 0.02) and a reduced median hospital stay (15 vs. 32 days).
• Medical therapy group showed significant increases in blood urea nitrogen and potassium levels (P < 0.02).

Conclusions:

• The peritoneovenous (LeVeen) shunt is an effective and beneficial treatment for massive cirrhotic ascites.
• The surgical procedure is associated with improved clinical outcomes, survival, and resource utilization.
• Contraindications include alcoholic hepatitis, hyperbilirubinemia, peritoneal sepsis, severe coagulopathy, and recent esophageal variceal bleeding.